BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Today, Zevia PBC, the zero sugar, naturally sweetened beverage company, announced it is expanding its Walmart distribution this month from +800 stores to now being available nationally in more than 4, ...

Tesla (TSLA) climbed over +13% in pre-market trading as the company’s CEO, Elon Musk, promoted Donald Trump throughout ... expected Q3 results and boosted its full-year guidance. Exact Sciences (EXAS) ...

Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...

Chairman and CEO. Guidance: Gilead Sciences raised its fiscal year 2024 adjusted EPS guidance from $3.60 – $3.90 to $4.25 – $4.45 compared to the consensus of $3.81. The company expects 2024 ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $105.00. Chris Schott has given his Buy rating due to a ...

In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $95.00. Tyler Van Buren’s rating is ...

Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead Sciences wasn’t one of them. The 10 stocks that made ...

The press release, slides, and supplementary data are available on the investors section of our website at gilead.com. The speakers on today’s call will be our Chairman and Chief Executive ...

Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...